Advertisement

Gadolinium Neutron Capture Therapy (GdNCT) with MRI Contrast Media. In Vitro Studies

  • R. Lawaczeck
  • C.-O. Fischer
  • U. Krüger
  • W. Leuther
  • J. Menrad

Abstract

Boron Neutron Capture Therapy (BNCT) is considered a promising therapy for the treatment of malignant brain tumors and malignant melanomas. Two boron compounds, the mercaptoundecahydro-closo-dodecaborate dianion ([B12H11,SH]2-, BSH) and boronophenylalanine (4-(dihydroxyboryl)phenylalanine, BPA), have entered the clinical research stage. (In both cases intracellular uptake by the target cells has been discussed.) For the evaluation of their pharmacokinetics and organ distribution, rather involved experimental techniques far from routine diagnostics are currently being used in treatment planning1, e.g. 18F-substitution in combination with PET or 11B MRI.

Keywords

U937 Cell Boron Neutron Capture Therapy Cell Doubling Time Proliferation Kinetic Neutron Capture Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    see this volume, e.g. contributions by: Y. Mishima; Y. Nakagawa & H. Hatanaka; H. Fukuda; K.M. Bradshaw et al.Google Scholar
  2. 2.
    G. Wolf, K.R. Burnett, E.J. Goldstein, and P.M. Joseph, Contrast agents for magnetic resonance imaging, in “Magnetic Resonance Annual’’, H.Y. Kressel, ed., Raven Press, New York, 1985, pp. 231–266.Google Scholar
  3. 3.
    R.F. Martin, G. D’Cunha, M. Pardee, B.J. Allen, Induction of double-strand breaks following neutron capture by DNA-bound15JGd. Int. J. Radiat. Biol. 54: 205–208, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    R.M. Brugger, J.A. Shih, Evaluation of Gadolinium-157 as a neutron therapy agent. Strahlenther Onkol. 165: 153–156, 1989.PubMedGoogle Scholar
  5. 5.
    Y. S. Ryabukhin, Integrated approach in the planning of neutron capture therapy. Strahlenther Onkol. 165: 158–162, 1989.PubMedGoogle Scholar
  6. 6.
    J.A. Shih, R.M. Brugger, Gadolinium as a neutron capture therapy agent. Med. Phys. 19: 733–744, 1992.PubMedCrossRefGoogle Scholar
  7. 7.
    J.T. Masiakowski, J.L. Horton, and L.J. Peters, Gadolinium neutron capture therapy for brain tumors: a computer study. Med. Phys. 19: 1–8, 1992.CrossRefGoogle Scholar
  8. 8.
    T. Matsumoto, Transport calculations of depth-dose distributions for gadolinium neutron capture therapy. Phys. Med. Biol. 37: 155–162, 1992PubMedCrossRefGoogle Scholar
  9. 9.
    Y. Akine, N. Tokita, T. Matsumoto, H. Oyama, S. Egawa, O. Aizawa, Radiation effect of gadolinium-neutron capture reactions on the survival of chinese hamster cells. Strahlenther. Onkol. 166: 831–833 1990.PubMedGoogle Scholar
  10. 10.
    M. Takagaki, Y. Oda, S. Miyatake, H. Kikuchi, T. Kobayashi, K. Kanda, Y. Ujeno, Killing effects of gadolinium neutron capture reactions on brain tumors, in “Progress in Neutron Capture Therapy tor Cancer’; B.J. Allen et al., eds. Plenum Press, New York, 1992, pp. 407–410.CrossRefGoogle Scholar
  11. 11.
    Y. Akine, N. Tokita, T. Matsumoto, H. Oyama, O. Aizawa, Gadolinium-neutron capture reactions: a radiobiological assay, in “Progress in Neutron Capture Therapy for Cancer”. B.J. Allen et al., eds., Plenum Press, New York, 1992, pp. 361–363.CrossRefGoogle Scholar
  12. 12.
    Y. Akine, N. Tokita, K. Tokuuye, M. Satoh, T. Kobayashi, K. Kanda, Electron-equivalent dose for the effect of Gadolinium neutron capture therapy on the growth of subcutaneously-inoculated Ehrlich tumor cells in mice. Jpn. J. Clin. Oncol. 23: N3, 145–148, 1993.Google Scholar
  13. 13.
    Y. Akine, N. Tokita, K. Tokuuye, M. Satoh, H. Churei, C. LePechoux, T. Kobayashi, and K. Kanda, Suppression of rabbit VX-2 subcutaneous tumor growth by Gadolinium Neutron Capture Therapy. Jpn. J. Cancer Res. 84: 841–843, 1993.PubMedCrossRefGoogle Scholar
  14. 14.
    C. Sundström and K. Nilsson, Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int. J. Cancer 17: 565–577, 1976.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • R. Lawaczeck
    • 1
    • 2
  • C.-O. Fischer
    • 1
    • 2
  • U. Krüger
    • 1
    • 2
  • W. Leuther
    • 1
    • 2
  • J. Menrad
    • 1
    • 2
  1. 1.Schering AG, Contrast Media Research and Institut für DiagnostikforschungBerlinGermany
  2. 2.Hahn-Meitner-InstitutBerlinGermany

Personalised recommendations